NASDAQ:HROW Harrow (HROW) Stock Price, News & Analysis $40.95 0.00 (0.00%) As of 08/21/2026 04:00 PM Eastern Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsInsider TradesNews and TrendsOptions ChainOwnershipSEC FilingsShort Interest About Harrow Stock (NASDAQ:HROW) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Harrow alerts:Sign Up Key Stats Today's Range$40.81▼$42.7050-Day Range$37.46▼$46.6552-Week Range$28.54▼$54.85Volume466,460 shsAverage Volume554,617 shsMarket Capitalization$1.54 billionP/E RatioN/ADividend YieldN/APrice Target$69.43Consensus RatingModerate Buy Company Overview Harrow Health, Inc. (NASDAQ: HROW) is a U.S.-based commercial-stage biopharmaceutical company specializing in ophthalmic therapeutics and diagnostics. The company focuses on the development, manufacturing and distribution of proprietary, generic and branded eye care products designed to treat a range of ocular conditions, including glaucoma, ocular hypertension, dry eye disease and other anterior segment disorders. Through its wholly owned affiliate ImprimisRx, Harrow Health offers a direct-to-physician model for customized formulations as well as low-cost generic alternatives. Its product portfolio includes preservative-free and compounded prescription eye drop formulations, which are distributed nationwide across all 50 states. The company leverages a targeted commercial infrastructure to support independent ophthalmologists, optometrists and surgical centers, while maintaining a research pipeline aimed at novel delivery technologies and formulations. Originally operating under the name ImprimisRx, the company officially adopted the Harrow Health name in mid-2021 to reflect its broader strategic focus on eye health. Harrow Health is led by Chairman and Chief Executive Officer Robert A. Ward, whose leadership, together with an experienced management team, has driven both commercial expansion and product innovation in the ophthalmology space.AI Generated. May Contain Errors. Read More Harrow Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks48th Percentile Overall ScoreHROW MarketRank™: Harrow scored higher than 48% of companies evaluated by MarketBeat, and ranked 527th out of 915 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.9 / 5Analyst RatingModerate Buy Consensus RatingHarrow has received a consensus rating of Moderate Buy. The company's average rating score is 2.55, and is based on no strong buy ratings, 8 buy ratings, 1 hold rating, and 2 sell ratings.Upside PotentialHarrow has a consensus price target of $69.43, representing about 69.5% upside from its current price of $40.95.Amount of Analyst CoverageHarrow has only been the subject of 3 research reports in the past 90 days.Read more about Harrow's stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Harrow is -40.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Harrow is -40.95, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioHarrow has a P/B Ratio of 29.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Harrow's valuation and earnings. Short Interest1.0 / 5Short Interest LevelBearish Percentage of Shares Shorted20.87% of the float of Harrow has been sold short.Short Interest Ratio / Days to CoverHarrow has a short interest ratio ("days to cover") of 11.77, which indicates bearish sentiment.Change versus previous monthShort interest in Harrow has recently decreased by 0.90%, indicating that investor sentiment is improving. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldHarrow does not currently pay a dividend.Dividend GrowthHarrow does not have a long track record of dividend growth. News and Social Media2.9 / 5News Sentiment0.71 News SentimentHarrow has a news sentiment score of 0.71. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This news sentiment score is similar to the average news sentiment of Healthcare companies.News Coverage This WeekMarketBeat has tracked 6 news articles for Harrow this week, compared to 5 articles on an average week.Search Interest4 people have searched for HROW on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Harrow to their MarketBeat watchlist in the last 30 days. This is a decrease of -50% compared to the previous 30 days. Company Ownership1.9 / 5Insider TradingSelling Shares Insider Buying vs. Insider SellingIn the past three months, Harrow insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $450,000.00 in company stock.Percentage Held by Insiders12.80% of the stock of Harrow is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions72.76% of the stock of Harrow is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Harrow's insider trading history. Receive HROW Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Harrow and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. HROW Stock News HeadlinesHarrow Announces IHEEZO® Data in Patient-Reported Discomfort Following Intravitreal InjectionsAugust 20, 2026 | globenewswire.comHarrow (NASDAQ:HROW) Insider Sells 11,250 Shares of StockAugust 18, 2026 | insidertrades.comSilicon Valley Insider: "Forget AI Stocks"A 25-year Silicon Valley veteran who recommended Nvidia before its 32,000 percent run says the next wave of AI gains wont come from Nvidia, Tesla, or SpaceX. He points to a detail buried on page 37 of the SpaceX IPO filing, tied to Elon Musks plans for 1 million AI satellites, 1 billion humanoid robots, and 200 billion AI chips a year. He says one overlooked sector could benefit most from this spending, and has identified a company trading under $1 that may factor into Musks supply chain.August 24 at 1:00 AM | Brownstone Research (Ad)Harrow, Inc. (NASDAQ:HROW) Given Consensus Rating of "Moderate Buy" by AnalystsAugust 16, 2026 | americanbankingnews.comHarrow (NASDAQ:HROW) Rating Increased to Hold at Wall Street ZenAugust 15, 2026 | americanbankingnews.comHC Wainwright Predicts Harrow's Q4 Earnings (NASDAQ:HROW)August 15, 2026 | americanbankingnews.comViatris (VTRS) is Selling Tyrvaya, but Could Harrow (HROW) Turn it Into a Growth Engine?August 13, 2026 | insidermonkey.comHarrow: The Q2 Turnaround Is Enough For A Cautious BuyAugust 13, 2026 | seekingalpha.comSee More Headlines HROW Stock Analysis - Frequently Asked Questions How have HROW shares performed this year? Harrow's stock was trading at $49.00 at the start of the year. Since then, HROW stock has decreased by 16.4% and is now trading at $40.95. How were Harrow's earnings last quarter? Harrow, Inc. (NASDAQ:HROW) released its quarterly earnings results on Monday, August, 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of ($0.18) by $0.28. The business had revenue of $70.66 million for the quarter, compared to analysts' expectations of $70.35 million. Harrow had a negative net margin of 13.51% and a negative trailing twelve-month return on equity of 38.00%. Read the conference call transcript. Who are Harrow's major shareholders? Harrow's top institutional investors include BlackRock Inc. (7.35%), Bamco Inc. NY (2.16%), Jupiter Topco LLC (1.54%) and Rice Hall James & Associates LLC (1.04%). Insiders that own company stock include Opaleye Management Inc, Mark L Baum, Andrew R Boll, Amir Shojaei and Adrienne L Graves. View institutional ownership trends. How do I buy shares of Harrow? Shares of HROW stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Harrow own? Based on aggregate information from My MarketBeat watchlists, some other companies that Harrow investors own include NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Tesla (TSLA), Visa (V), Netflix (NFLX) and JPMorgan Chase & Co. (JPM). Company Calendar Last Earnings8/10/2026Today8/24/2026Next Earnings (Estimated)11/09/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1w+) 1-Year History Aug 25 Nov 25 Feb 26 May 26 Aug 26 For the last 10 days, HROW's financial health has been in the Green zone, according to TradeSmith. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorHealthcare Industry Pharmaceuticals Sub-IndustryPharmaceuticals Current SymbolNASDAQ:HROW Previous SymbolNASDAQ:HROW CIK1360214 Webwww.harrowinc.com Phone(615) 733-4730Fax858-345-1745Employees180Year Founded2012Price Target and Rating Average Price Target for Harrow$69.43 High Price Target$88.00 Low Price Target$63.00 Potential Upside/Downside+69.5%Consensus RatingModerate Buy Rating Score (0-4)2.55 Research Coverage11 Analysts Profitability EPS (Trailing Twelve Months)($1.00) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$5.14 million Net Margins-13.51% Pretax Margin-12.13% Return on Equity-38.00% Return on Assets-3.37% Debt Debt-to-Equity Ratio19.70 Current Ratio2.24 Quick Ratio2.08 Sales & Book Value Annual Sales$275.59 million Price / Sales5.57 Cash Flow$0.86 per share Price / Cash Flow47.38 Book Value$1.41 per share Price / Book29.04Miscellaneous Outstanding Shares37,488,000Free Float32,690,000Market Cap$1.54 billion OptionableOptionable Beta0.28 Social Links 7 Stocks to Buy Before the Robotics RevolutionRobotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming to the United States, and there are four ways that investors can gain exposure to this new robotics revolution. Plus, learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.Get This Free Report This page (NASDAQ:HROW) was last updated on 8/24/2026 by MarketBeat.com Staff. From Our PartnersI found Rolls-Royce at $2 - now I see the same setup againIn 2022, Karim Rahemtulla recommended Rolls-Royce under $2 - a misunderstood aerospace name the market had wri...Monument Traders Alliance | SponsoredA Simple Guide to Options Trading While It's Still FreeA free copy of Options Trading Made Simple is available now but wont stay that way for long. Chris Rowe cal...True Market Insiders | SponsoredThese gold assets are priced for $1,800 gold [it's over $4,000]Gold's major miners are generating record free cash flow, with margins as high as 75 percent even after gold's...Golden Portfolio | SponsoredThey didn't warn anyone in 1971. This time someone is warning you.On August 15, 1971, Nixon interrupted prime-time television and ended the gold standard in 15 minutes - no deb...Reagan Gold Group | SponsoredThe retirement stock I'd buy before Nvidia todayIn 2014, Marc Chaikin pointed readers toward Nvidia. Now the 60-year Wall Street veteran and creator of the Ch...Chaikin Analytics | SponsoredA $382 trillion migration and the position no one is talking aboutTrump just signed a law requiring America's entire $382 trillion financial system to migrate to a new money ne...Awesomely | SponsoredThe trade I’ve been waiting for since 2011Ross Givens, Director of Research at Traders Agency, is calling for gold to reach $10,000 an ounce this superc...Traders Agency | SponsoredFree Stock Pick: The Company First in Line for America’s New Super FuelThe U.S. Army and Department of Energy are launching Project Janus - a high-priority initiative ordered by Pre...Banyan Hill Publishing | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Harrow, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Harrow With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
